355 related articles for article (PubMed ID: 24788576)
41. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant and Adjuvant Treatment with Denosumab in Aggressive Giant-cell Tumor of Bone in the Proximal Fibula: a Case Report.
Marinova VV; Slavchev SA; Patrikov KD; Tsenova PM; Georgiev GP
Folia Med (Plovdiv); 2018 Dec; 60(4):637-640. PubMed ID: 31188771
[TBL] [Abstract][Full Text] [Related]
43. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
[TBL] [Abstract][Full Text] [Related]
44. Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation.
Langevelde KV; Vucht NV; Tsukamoto S; Mavrogenis AF; Errani C
Curr Med Imaging; 2022; 18(2):162-169. PubMed ID: 33845749
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
46. Malignant Sarcomatous Transformation of Benign Giant Cell Tumor of Bone after Treatment with Denosumab Therapy: A Literature Review of Reported Cases.
Alaqaili SI; Abduljabbar AM; Altaho AJ; Khan AA; Alherabi JA
Cureus; 2018 Dec; 10(12):e3792. PubMed ID: 30868006
[TBL] [Abstract][Full Text] [Related]
47. Significance of Histone H3.3 (G34W)-Mutant Protein in Pathological Diagnosis of Giant Cell Tumor of Bone.
Miskad UA; Syamsul F; Dahlan H; Sungowati NK; Achmad D; Johan MP
Asian Pac J Cancer Prev; 2023 May; 24(5):1737-1741. PubMed ID: 37247296
[TBL] [Abstract][Full Text] [Related]
48. Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls.
Li H; Gao J; Gao Y; Lin N; Zheng M; Ye Z
Front Oncol; 2020; 10():580605. PubMed ID: 33123484
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
50. Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort.
Boye K; Jebsen NL; Zaikova O; Knobel H; Løndalen AM; Trovik CS; Monge OR; Hall KS
Acta Oncol; 2017 Mar; 56(3):479-483. PubMed ID: 28105885
[TBL] [Abstract][Full Text] [Related]
51. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
[TBL] [Abstract][Full Text] [Related]
52. Giant cell tumor of bone: An update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses.
Rekhi B; Dave V
Histol Histopathol; 2023 Feb; 38(2):139-153. PubMed ID: 35766228
[TBL] [Abstract][Full Text] [Related]
53. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
54. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
55. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
56. Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab.
Chandler A; Bartelstein MK; Fujiwara T; Antonescu CR; Healey JH; Vaynrub M
BMC Musculoskelet Disord; 2021 Apr; 22(1):320. PubMed ID: 33794838
[TBL] [Abstract][Full Text] [Related]
57. The clinical approach toward giant cell tumor of bone.
van der Heijden L; Dijkstra PD; van de Sande MA; Kroep JR; Nout RA; van Rijswijk CS; Bovée JV; Hogendoorn PC; Gelderblom H
Oncologist; 2014 May; 19(5):550-61. PubMed ID: 24718514
[TBL] [Abstract][Full Text] [Related]
58. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone.
Borkowska A; Goryń T; Pieńkowski A; Wągrodzki M; Jagiełło-Wieczorek E; Rogala P; Szacht M; Rutkowski P
Oncol Lett; 2016 Dec; 12(6):4312-4318. PubMed ID: 28101196
[TBL] [Abstract][Full Text] [Related]
59. Radiological findings of denosumab treatment for giant cell tumours of bone.
van Langevelde K; McCarthy CL
Skeletal Radiol; 2020 Sep; 49(9):1345-1358. PubMed ID: 32335707
[TBL] [Abstract][Full Text] [Related]
60. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
